AbbVie hikes full-year earnings guidance as Humira sales top estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbvie (ABBV) PT Raised to $200 at Goldman Sachs
July 26, 2024 5:53 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "Even amidst expectations that Immunology would once again deliver, we see basis for the factors underpinning growth for both Skyrizi and Rinvoq to continue propelling upside - including NBRx dynamics that... More
William Blair Reiterates Outperform Rating on Abbvie (ABBV)
July 26, 2024 5:37 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).
The analyst comments "Stock thoughts: We believe AbbVie has a strong and durable growth profile over the coming years thanks to its strong growth platform, recently augmented by the... More
Abbvie (ABBV) PT Raised to $210 at Truist Securities
July 25, 2024 4:12 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "ABBV reported strong 2Q24 results with top and bottom line beats, led by Skyrizi/RInvoq. Given the share... More
Abbvie (ABBV) PT Raised to $210 at JPMorgan
July 25, 2024 3:56 PM EDTJPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight rating.
The analyst comments "Exiting 2Q results, we our updating our model and wanted to share our key changes. Overall, we are increasing our estimates to... More
AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance
July 25, 2024 7:50 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $2.65, $0.05 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.02 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of $10.71-$10.91, versus the consensus of $10.90.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More